$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

$vbivq Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224019796 Filed on May 15, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$1.214M	$485.0K
YoY Change	150.31%	284.92%
Cost Of Revenue	$2.724M	$3.559M
YoY Change	-23.46%	29.23%
Gross Profit	-$1.510M	-$3.074M
YoY Change	-50.88%	16.97%
Gross Profit Margin	-124.38%	-633.81%
Selling, General & Admin	$7.671M	$13.28M
YoY Change	-42.25%	21.54%
% of Gross Profit
Research & Development	$2.571M	$3.151M
YoY Change	-18.41%	33.4%
% of Gross Profit
Depreciation & Amortization	$493.0K	$508.0K
YoY Change	-2.95%	7.4%
% of Gross Profit
Operating Expenses	$12.97M	$19.99M
YoY Change	-35.15%	50.42%
Operating Profit	-$11.75M	-$19.51M
YoY Change	-39.76%	22.54%
Interest Expense	$1.818M	$1.429M
YoY Change	27.22%	-126.79%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$17.90M	-$27.75M
YoY Change	-35.5%	30.57%
Income Tax
% Of Pretax Income
Net Earnings	-$17.90M	-$27.75M
YoY Change	-35.5%	30.57%
Net Earnings / Revenue	-1474.46%	-5721.86%
Basic Earnings Per Share	-$0.73	-$3.22
Diluted Earnings Per Share	-$0.73	-$3.22
COMMON SHARES
Basic Shares Outstanding	24.58M shares	258.3M shares
Diluted Shares Outstanding	24.58M shares	8.609M shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.60M	$40.39M
YoY Change	-68.82%	-60.14%
Cash & Equivalents	$12.60M	$40.39M
Short-Term Investments
Other Short-Term Assets	$1.994M	$1.976M
YoY Change	0.91%	-51.59%
Inventory	$9.944M	$6.768M
Prepaid Expenses	$1.601M	$2.419M
Receivables	$227.0K	$281.0K
Other Receivables	$1.508M	$1.203M
Total Short-Term Assets	$26.36M	$51.84M
YoY Change	-49.15%	-53.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.088M	$11.69M
YoY Change	-22.26%	-20.43%
Goodwill	$1.107M	$2.132M
YoY Change	-48.08%
Intangibles	$35.73M	$58.50M
YoY Change	-38.92%
Long-Term Investments
YoY Change
Other Assets	$1.206M	$1.311M
YoY Change	-8.01%	-9.34%
Total Long-Term Assets	$49.08M	$76.63M
YoY Change	-35.95%	-6.16%
TOTAL ASSETS
Total Short-Term Assets	$26.36M	$51.84M
Total Long-Term Assets	$49.08M	$76.63M
Total Assets	$75.44M	$128.5M
YoY Change	-41.27%	-33.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.871M	$9.837M
YoY Change	-9.82%	150.5%
Accrued Expenses	$6.188M	$12.18M
YoY Change	-49.2%	-16.98%
Deferred Revenue	$9.619M	$649.0K
YoY Change	1382.13%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$48.75M
YoY Change
Total Short-Term Liabilities	$77.59M	$29.57M
YoY Change	162.38%	-13.0%
LONG-TERM LIABILITIES
Long-Term Debt		$49.36M
YoY Change		99.12%
Other Long-Term Liabilities	$3.316M	$4.507M
YoY Change	-26.43%	-20.41%
Total Long-Term Liabilities	$3.316M	$53.87M
YoY Change	-93.84%	76.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.59M	$29.57M
Total Long-Term Liabilities	$3.316M	$53.87M
Total Liabilities	$80.91M	$83.44M
YoY Change	-3.03%	29.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$600.3M	-$517.4M
YoY Change	16.04%
Common Stock	$563.1M	$534.3M
YoY Change	5.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.467M	$45.02M
YoY Change
Total Liabilities & Shareholders Equity	$75.44M	$128.5M
YoY Change	-41.27%	-33.79%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$17.90M	-$27.75M
YoY Change	-35.5%	30.57%
Depreciation, Depletion And Amortization	$493.0K	$508.0K
YoY Change	-2.95%	7.4%
Cash From Operating Activities	-$11.77M	-$21.66M
YoY Change	-45.65%	8.69%
INVESTING ACTIVITIES
Capital Expenditures	$151.0K	$534.0K
YoY Change	-71.72%	-203.69%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$151.0K	-$534.0K
YoY Change	-71.72%	3.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$868.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$843.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-$11.77M	-$21.66M
Cash From Investing Activities	-$151.0K	-$534.0K
Cash From Financing Activities	$843.0K
Net Change In Cash	-$11.09M	-$22.24M
YoY Change	-50.13%	8.86%
FREE CASH FLOW
Cash From Operating Activities	-$11.77M	-$21.66M
Capital Expenditures	$151.0K	$534.0K
Free Cash Flow	-$11.92M	-$22.19M
YoY Change	-46.28%	14.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000764195
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	VBI Vaccines Inc/BC
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	VBIV	Promissory Note Issued By Brii Biosciences Limited In Favor Of K2 Health Ventures PromissoryNoteIssuedByBriiBiosciencesLimitedInFavorOfK2HealthVentures		usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023	VBIV	Contract With Customer Liability Amount Received ContractWithCustomerLiabilityAmountReceived		usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2023	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-37769
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	160 Second Street
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2024Q1	dei	City Area Code CityAreaCode	617
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	830-3031
CY2024Q1	dei	Security12b Title Security12bTitle	Common Shares, no par value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	VBIV
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28682275	shares
CY2024Q1	us-gaap	Cash Cash	12595000	usd
CY2023Q4	us-gaap	Cash Cash	23685000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	227000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	9944000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8499000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1601000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2284000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1994000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1763000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	26361000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	36231000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1206000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1178000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9088000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9665000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1947000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2248000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35734000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	36499000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1107000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1130000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	49082000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	50720000	usd
CY2024Q1	us-gaap	Assets Assets	75443000	usd
CY2023Q4	us-gaap	Assets Assets	86951000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8871000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6431000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9528000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10284000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9619000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7276000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	831000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	976000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	48745000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	50769000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	77594000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	75736000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1608000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1832000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1136000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1295000	usd
CY2024Q1	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	572000	usd
CY2023Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	561000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3316000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3688000	usd
CY2024Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25236766	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25236766	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23918983	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23918983	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	455057000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	454214000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	108010000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	107431000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	31811000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28327000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-600345000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-582445000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5467000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7527000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75443000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86951000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1214000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485000	usd
CY2024Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2724000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3559000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2571000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3151000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7671000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13284000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	12966000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	19994000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11752000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19509000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1818000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1429000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4330000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6813000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17900000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27751000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-17900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3484000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6599000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14416000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21152000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.22
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.22
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24584798	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24584798	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8608539	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8608539	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7527000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	843000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	579000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-17900000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3484000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5467000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2011000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6599000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	45022000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-17900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	493000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	508000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	579000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2011000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	476000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	470000	usd
CY2024Q1	VBIV	Inventory Reserve InventoryReserve	657000	usd
CY2023Q1	VBIV	Inventory Reserve InventoryReserve	263000	usd
CY2024Q1	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-397000	usd
CY2023Q1	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-333000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-4222000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-6895000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	238000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	185000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2223000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	599000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-677000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	118000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	260000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4089000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-6000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-28000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2509000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3204000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-232000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-533000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4073000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-400000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-334000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11770000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21656000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	534000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-151000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-534000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	868000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	25000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	843000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-12000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-47000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11090000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22237000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23685000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62629000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12595000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40392000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1565000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1437000	usd
CY2024Q1	VBIV	Promissory Note Issued By Brii Biosciences Limited In Favor Of K2 Health Ventures PromissoryNoteIssuedByBriiBiosciencesLimitedInFavorOfK2HealthVentures	2500000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	45000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	120000	usd
CY2024Q1	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
CY2023Q1	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zpSoDpgFnAv9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82F_zneta2gkbKn3">NATURE OF BUSINESS AND CONTINUATION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (the “Company” or “VBI”) was incorporated under the laws of British Columbia, Canada on April 9, 1965.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc., a Canadian company and the wholly owned subsidiary of VBI US (“VBI Cda”); SciVac Ltd., an Israeli company (“SciVac”); SciVac Hong Kong Limited, a company incorporated pursuant to the Companies Ordinance (Chapter 622 of the Laws of HongKong) and a wholly owned subsidiary (“SciVac HK”); and VBI Vaccines B.V, a Netherlands company and a wholly owned subsidiary (“VBI BV”), are collectively referred to as the “Company”, “we”, “us”, “our”, or “VBI”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s registered office is located at Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 with its principal office located at 160 Second Street, Floor 3, Cambridge, MA 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI is a commercial-stage biopharmaceutical company driven by immunology in the pursuit of prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA-launched eVLP (“MLE”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B (“HBV”), COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Partnership with Brii Bio</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 5, 2023, the Company announced the expansion of its hepatitis B partnership with Brii Biosciences Limited (“Brii Bio”). Through (i) a Collaboration and License Agreement (the “Collaboration Agreement”), dated July 5, 2023, by and between the Company and Brii Bio, and (ii) the Amended and Restated Collaboration and License Agreement (the “A&R Collaboration Agreement, and together with the Collaboration Agreement, the “Brii Collaboration Agreements”), dated July 5, 2023, by and between the Company and Brii Bio, Brii Bio expanded its exclusive license to VBI-2601 to global rights and acquired an exclusive license for PreHevbri in Asia Pacific (“APAC”), excluding Japan. As part of this collaboration, Brii Bio paid the Company an upfront payment of $<span id="xdx_909_ecustom--UpfrontPayment_pn3n3_c20230704__20230705_z7OYV03bUzha" title="Upfront payment">15,000</span> consisting of a $<span id="xdx_900_eus-gaap--EquityMethodInvestmentAggregateCost_iI_pn3n3_c20230705_zdQjc386yxml" title="Equity investment">3,000</span> equity investment in a concurrent registered direct offering, $<span id="xdx_90D_ecustom--PaymentClinicalAndCommercialManufacture_iI_pn3n3_c20230705_zEmsrmlA3bI6" title="Payment for clinical and commercial manufacture">5,000</span> as an advance payment for the clinical and commercial manufacture and supply of VBI-2601 and PreHevbri and any related manufacturing expenditures pursuant to a supply agreement (the “Supply Agreement”) dated July 5, 2023, by and between the Company and Brii Bio, and $<span id="xdx_900_ecustom--NonrefundableUpfrontPayment_iI_pn3n3_c20230705_zm2vlSjypl57" title="Non-refundable upfront payment">7,000</span> as a non-refundable upfront payment pursuant to the Brii Collaboration Agreements. In addition, pursuant to the Letter Agreement (the “Letter Agreement”), dated July 5, 2023, by and among the Company, SciVac, and Brii Bio, the Company also granted to Brii Bio a security interest, subject to a Subordination Agreement between Brii Bio and K2 HealthVentures LLC (“K2HV”), in all of its respective right, title, and interest in and to all intellectual property, know-how, and licenses to the extent related to PreHevbri and VBI-2601, and all proceeds of the foregoing, in order to secure performance of all of the Company’s obligations under the Brii Collaboration Agreements, the Supply Agreement, and the Loan Agreement (each as defined herein).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 13, 2024, the Company entered into a series of agreements with Brii Bio, pursuant to which, subject to achievement of certain activities, we would receive up to $<span id="xdx_904_eus-gaap--AssetAcquisitionPriceOfAcquisitionExpected_pn3n3_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--AssetAcquisitionAxis__custom--BriiBiosciencesLimitedMember_z2GjDkOps69a" title="Asset acquisition, consideration expected">33,000</span> in consideration from Brii Bio, consideration which will be used to correspondingly reduce our obligations due under the Loan and Guaranty Agreement (“Loan Agreement”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Rehovot Purchase Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 13, 2024, the Company and SciVac entered into a purchase agreement (the “Rehovot Purchase Agreement”) with Brii Bio Israel Ltd (“Brii Israel”), a wholly-owned subsidiary of Brii Bio, prior to the closing, and joined as a party to the agreement prior to the closing as the purchaser, and Brii Biosciences, Inc, a Delaware corporation, pursuant to which, upon achievement of certain activities and closing of the transactions contemplated by the Rehovot Purchase Agreement, subject to the terms and conditions therein, SciVac will sell to Brii Israel certain assets, including SciVac and its affiliates’ interest and rights in certain leases with respect to the vaccine manufacturing facility in Israel, for an aggregate purchase price of $<span id="xdx_901_eus-gaap--AssetAcquisitionPriceOfAcquisitionExpected_pn3n3_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--RehovotPurchaseAgreementMember__us-gaap--AssetAcquisitionAxis__custom--BriiBioIsraelLtdMember_zX7fKAP9vzl9" title="Asset acquisition, consideration expected">10,000</span>, which is then required to be paid to K2 HealthVentures (“K2HV”) pursuant to the terms of the Fourth Amendment (as defined below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Rehovot Purchase Agreement contains representations and warranties of SciVac and Brii Israel that are typical for transactions of this type. The Rehovot Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The closing of the transactions pursuant to the Rehovot Purchase Agreement are subject to the terms and conditions therein, including closing conditions that are typical for transactions of this type and the Company’s completion of the Essential Activities (as defined below). Closing will not occur prior to June 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Brii Purchase Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 13, 2024, the Company and VBI Cda entered into a Purchase Agreement with Brii Bio (the “Brii Purchase Agreement”), pursuant to which, upon achievement of certain activities, the Company and VBI Cda will sell, transfer, convey and assign to Brii Bio, substantially all of the intellectual property related to VBI-2601 owned by the Company and VBI Cda, for a secured promissory note in the principal amount up to $<span id="xdx_907_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_pn3n3_c20240213__us-gaap--TypeOfArrangementAxis__custom--BriiPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteMember__srt--RangeAxis__srt--MaximumMember_zXDbnjqZfl1b">10,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “Note”) to be issued by Brii Bio, which is then required to be assigned to K2HV pursuant to the terms of the Fourth Amendment (as defined below), in exchange for a reduction in the Company’s obligations under the Loan Agreement equal to the initial principal amount of the Note. The Note was issued to Brii Bio on February 13, 2024. The initial principal amount of the Note is $<span id="xdx_902_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_pn3n3_c20240213__us-gaap--TypeOfArrangementAxis__custom--BriiPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteMember_zhyyl02WmZvd">2,500</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which shall be increased by an aggregate amount equal to $<span id="xdx_904_ecustom--MaximumAmountOfNotesAndLoansReceivableExpectedToIncrease_pn3n3_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--BriiPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteMember_zDpzCPU9KOm4">7,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon the Company’s obtaining applicable consents under the license agreement between Savient Pharmaceuticals Inc. and SciGen Ltd dated June 2004 and subsequently amended and restated effective September 1, 2021 (the “Amended and Restated Ferring License Agreement”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Brii Side Letter</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 13, 2024, the Company and Brii Bio entered into a side letter (the “Side Letter”) setting forth certain essential and additional priority activities to transfer manufacturing responsibility for clinical supply and commercial supply of VBI-2601 and PreHevbri for the Brii Territories set forth in the Side Letter (the “Essential Activities”) the Company is required to complete as a condition to the entry into the License Agreement (as defined below) and consummation of the transactions pursuant to the Rehovot Purchase Agreement. As of March 31, 2024, the Essential Activities were still in progress and not yet completed. The principal amount of the Note shall increase up to $<span id="xdx_90C_ecustom--MaximumAmountOfNotesAndLoansReceivable_pn3n3_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--BriiSideLetterMember__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteMember_zOhQaB7PTwgh" title="Principal amount of note">18,000</span> upon completion of the Essential Activities and the Company’s obligations under the Loan Agreement shall be reduced by a corresponding amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Brii License Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Upon completion of the Essential Activities pursuant to the Side Letter, VBI Cda and Brii Bio will enter into a license agreement (the “Brii License Agreement”) pursuant to which Brii Bio shall issue a secured promissory note in the amount of $<span id="xdx_90C_eus-gaap--SecuredDebt_iI_pn3n3_c20240213__us-gaap--TypeOfArrangementAxis__custom--BriiLicenseAgreementMember_zHQhMug5eQQj">5,000 </span>as consideration for a perpetual, royalty-free, milestone-free, sublicensable, fully-paid, and exclusive license to the GBM program (VBI-1901) for development and commercialization in the APAC region (excluding Japan), which such note is then required to be assigned to K2HV pursuant to the terms of the Fourth Amendment. The entry by VBI Cda and Brii Bio into the Brii License Agreement is subject to the Company completing the Essential Activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Loan Agreement and Forbearance Agreement with K2HV</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On each of January 9, 2024, January 23, 2024, and February 6, 2024, as discussed in Note 9, the Loan Parties entered into extensions to the Forbearance Agreement. Additionally, on February 13, 2024, as discussed in Note 9, the Loan Parties entered into the Fourth Amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company faces a number of risks, including but not limited to, uncertainties regarding the success of the development and commercialization of its products, demand and market acceptance of the Company’s products, and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240331_zSoIWoPRZGBh" title="Accumulated deficit">600,345</span> and cash of $<span id="xdx_902_eus-gaap--Cash_iI_pn3n3_c20240331_zC3b6CDWlVr9">12,595</span> as of March 31, 2024. Cash flows used in operating activities were $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240331_z1zVVpiIPkX1" title="Cash outflows from operating activities">11,770</span> for the three months ended March 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will require significant additional funds to conduct clinical and non-clinical trials, achieve and maintain regulatory approvals, and commercially launch and sell our approved products. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, government or non-governmental organization grants or subsidies, and/or revenues from potential business development transactions, if any. There is no assurance the Company will manage to obtain these sources of financing, if required. Based on available cash at March 31, 2024, together with the net proceeds from the April 2024 Offering (defined below), in order to continue to fund our operations, we must raise additional equity or debt capital in the near term and cannot provide any assurance that we will be successful in doing so. If we are unable to obtain additional financing in the near future, we may be required to pursue a reorganization proceeding, including under applicable bankruptcy or insolvency laws. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATM Program</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2022, the Company 1) filed a registration statement on Form S-3 (File No. 333-267109), which included a base prospectus which covers the offering, issuance and sale of up to $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220825__20220826__srt--RangeAxis__srt--MaximumMember_zgIiykjBfwTl">300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of common shares, warrants, units and/or subscription rights; and 2) entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”), pursuant to which the Company may offer and sell its common shares having an aggregate price of up to $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember__srt--RangeAxis__srt--MaximumMember_zpH4TzqIzaza">125,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from time to time through Jefferies, acting as agent or principal (the “Jefferies ATM Program”). During the three months ended March 31, 2024, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zxZILomXyOXc">1,317,783 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common shares under the Jefferies ATM Program, for total gross proceeds of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zQ1oRou8pXl9">868 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a weighted average price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_ziwuv95uMrd">0.6589 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company incurred $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zcIkvgnVpYff">25 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in sales agent commissions and share issuance costs related to the common shares issued during the three months ended March 31, 2024, resulting in net proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_z1hVQOoP8Lqd">843</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company terminated the Jefferies ATM Program on May 9, 2024, effective as of May 10, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 16, 2024, upon filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, the Company became subject to General Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common shares in a registered primary offering using Form S-3 with a value exceeding more than one-third of our public float in any 12 calendar month period so long as our public float remains below $<span id="xdx_908_ecustom--PublicFloatValue_iI_pn3n3_c20240416__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zghdzjsHBtI4" title="Public float value">75,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April 2024 Registered Direct Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 9, 2024, the Company entered into a securities purchase agreement (the “April 2024 Purchase Agreement”) with certain institutional investors named therein pursuant to which the Company issued and sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240409__20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourRegisteredDirectOfferingMember__us-gaap--TypeOfArrangementAxis__custom--AprilTwoThousandTwentyFourPurchaseAgreementMember_zL8Dpcpz9Kkf" title="Number of shares issued">2,272,728</span> common shares and accompanying warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourRegisteredDirectOfferingMember_ziCU2fNIhWY2" title="Warrants to purchase shares">2,272,728</span> common shares (the “April 2024 Warrants”) at a combined offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourRegisteredDirectOfferingMember_z0g8d7wt8Zjh" title="Shares issued price">0.88</span> per common share and accompanying April 2024 Warrant in a registered direct offering (the “April 2024 Offering”). The April 2024 Offering closed on April 11, 2024. The April 2024 Warrants have an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourRegisteredDirectOfferingMember_z2WOMW3qjJGe" title="Warrants exercise price">0.76</span> per share, are immediately exercisable on the date of issuance, and expire five years following the date of issuance. Net proceeds to us from the April 2024 Offering, after deducting placement agent fees and estimated offering expenses payable by us, were approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20240409__20240409__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AprilTwoThousandTwentyFourRegisteredDirectOfferingMember_zdohJmqBZmz9" title="Proceeds from issuance of shares">1,700</span>. In connection with the April 2024 Offering, the Company also issued to H.C. Wainwright & Co., LLC or its designees, placement agent warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240409__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z41ZuQoqc1Bd" title="Warrants to purchase shares">136,364</span> common shares (the “April 2024 Placement Agent Warrants”) as compensation in connection with the April 2024 Offering. The April 2024 Placement Agent Warrants have substantially the same terms and conditions as the April 2024 Warrants, except that the April 2024 Placement Agent Warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240409__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlf9GVRXLRE3" title="Warrants exercise price">1.10</span> per share, which represents 125% of the offering price per common share and accompanying April 2024 Warrant and expire five years following the commencement of sales pursuant to the April 2024 Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq Minimum Bid Price Requirement – Extension of Compliance Period</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported, on November 1, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common shares for the 30 consecutive business day period between September 19, 2023, through October 31, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until April 29, 2024 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 30, 2024, the Company received a letter from the Nasdaq Stock Market notifying the Company that the Company has been granted an additional 180-day period, or until October 28, 2024, to regain compliance with the Minimum Bid Price Requirement. The new compliance period is an extension of the initial Compliance Period provided for in Nasdaq’s deficiency notice to the Company, dated November 1, 2023. The Nasdaq Stock Market’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the Minimum Bid Price Requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If compliance with the Minimum Bid Price Requirement cannot be demonstrated by October 28, 2024, the Nasdaq Stock Market will provide written notification that the Company’s common shares could be delisted. In such event, Nasdaq rules permit the Company to appeal any delisting determination to a Nasdaq Hearings Panel. Accordingly, there can be no assurance that the Company will be able to regain compliance with the Nasdaq listing rules or maintain its listing on Nasdaq. The Company has not regained compliance as of the date of this Form 10-Q, and if it fails to regain compliance by October 28, 2024, its common shares will be subject to delisting by Nasdaq, which could seriously decrease or eliminate the value of an investment in the common shares and result in significantly increased uncertainty as to the Company’s ability to raise additional capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments recognized in the condensed consolidated balance sheet consist of cash, accounts receivable, other current assets, accounts payable, and other current liabilities. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	VBIV	Upfront Payment UpfrontPayment	15000000	usd
CY2023Q3	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	3000000	usd
CY2023Q3	VBIV	Payment Clinical And Commercial Manufacture PaymentClinicalAndCommercialManufacture	5000000	usd
CY2023Q3	VBIV	Nonrefundable Upfront Payment NonrefundableUpfrontPayment	7000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-600345000	usd
CY2024Q1	us-gaap	Cash Cash	12595000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11770000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	899000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1661000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	3398000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2734000	usd
CY2024Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	5647000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4104000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	9944000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8499000	usd
CY2024Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	1508000	usd
CY2023Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	1268000	usd
CY2024Q1	VBIV	Other Current Assets OtherCurrentAssets	486000	usd
CY2023Q4	VBIV	Other Current Assets OtherCurrentAssets	495000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1994000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1763000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	765000	usd
CY2024Q1	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	7292000	usd
CY2024Q1	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-315000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1107000	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	7292000	usd
CY2023Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-292000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1130000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	23000	usd
CY2024Q1	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1570000	usd
CY2023Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	2018000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1815000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1674000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1972000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1934000	usd
CY2024Q1	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	3166000	usd
CY2023Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	3601000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1005000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1057000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9528000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10284000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16312871	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1128106	shares
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	48745000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	50769000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	48745000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	50769000	usd
CY2024Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	46456000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	48077000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1538000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1461000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	476000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	470000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	196000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	502000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1818000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1429000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	579000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2011000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1214000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	11227000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9108000	usd
CY2024Q1	VBIV	Contract With Customer Liability Amount Received ContractWithCustomerLiabilityAmountReceived	2500000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	244000	usd
CY2024Q1	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation	137000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11227000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9619000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1608000	usd
CY2020Q3	VBIV	Contribution Agreement Description ContributionAgreementDescription	75% of VBI Cda’s costs incurred in respect of the Project, subject to certain eligibility limitations as set forth in the Contribution Agreement and (ii) CAD $55,976 from the SIF to support the development of our coronavirus vaccine program, VBI-2900, though Phase II clinical studies (the “Project”).
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	452000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	491000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M26D
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	836000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	663000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	584000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	160000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2243000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	276000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1967000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	831000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1136000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1214000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485000	usd

Files In Submission

Name	View Source	Status
vbiv-20240331_cal.xml	Edgar Link	unprocessable
0001493152-24-019796-index-headers.html	Edgar Link	pending
0001493152-24-019796-index.html	Edgar Link	pending
0001493152-24-019796.txt	Edgar Link	pending
0001493152-24-019796-xbrl.zip	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex10-9.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vbiv-20240331.xsd	Edgar Link	pending
vbiv-20240331_def.xml	Edgar Link	unprocessable
vbiv-20240331_lab.xml	Edgar Link	unprocessable
vbiv-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

2024 Q1 Form 10-Q Financial Statement

#000149315224019796 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ VBI Vaccines Inc/BC Stock $vbivq

2024 Q1 Form 10-Q Financial Statement

#000149315224019796 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq